103 related articles for article (PubMed ID: 1525608)
1. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities.
van Lochem E; de Gast B; Goulmy E
Bone Marrow Transplant; 1992 Aug; 10(2):181-3. PubMed ID: 1525608
[TBL] [Abstract][Full Text] [Related]
2. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction.
Montagna D; Daudt L; Locatelli F; Montini E; Turin I; Lisini D; Giorgiani G; Bernardo ME; Maccario R
Cancer Res; 2006 Jul; 66(14):7310-6. PubMed ID: 16849581
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
4. Minor histocompatibility antigens, defined by graft-vs.-host disease-derived cytotoxic T lymphocytes, show variable expression on human skin cells.
De Bueger M; Bakker A; Van Rood JJ; Goulmy E
Eur J Immunol; 1991 Nov; 21(11):2839-44. PubMed ID: 1682155
[TBL] [Abstract][Full Text] [Related]
5. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity.
Faber LM; van Luxemburg-Heijs SA; Veenhof WF; Willemze R; Falkenburg JH
Blood; 1995 Oct; 86(7):2821-8. PubMed ID: 7670118
[TBL] [Abstract][Full Text] [Related]
6. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
[TBL] [Abstract][Full Text] [Related]
7. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
[TBL] [Abstract][Full Text] [Related]
8. Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation.
Marijt WA; Kernan NA; Diaz-Barrientos T; Veenhof WF; O'Reilly RJ; Willemze R; Falkenburg JH
Bone Marrow Transplant; 1995 Jul; 16(1):125-32. PubMed ID: 7581111
[TBL] [Abstract][Full Text] [Related]
9. [Graft-versus-leukemia effect by lymphocytes from the first donor after second cord blood transplantation in a patient with T-lymphoblastic lymphoma].
Nagai K; Hashimoto H; Itoh K; Matsushita A; Shimoji S; Kimura T; Inoue D; Mori M; Nagai Y; Tabata S; Yanagida M; Takahashi T
Rinsho Ketsueki; 2010 Jun; 51(6):413-21. PubMed ID: 20622488
[TBL] [Abstract][Full Text] [Related]
10. Autoreactive T cells isolated during graft-versus-host disease (GvHD) may be involved in the generation of an anti-leukemic effect after bone marrow transplantation (BMT).
Schneider EM; Dörre S; Wernet P
Transplant Proc; 1989 Feb; 21(1 Pt 3):3018-21. PubMed ID: 2650416
[No Abstract] [Full Text] [Related]
11. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
12. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.
Faber LM; van der Hoeven J; Goulmy E; Hooftman-den Otter AL; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
J Clin Invest; 1995 Aug; 96(2):877-83. PubMed ID: 7635982
[TBL] [Abstract][Full Text] [Related]
13. Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1.
Kasai M; Akatsuka Y; Emi N; Taji H; Kohno A; Abe A; Tanimoto M; Kodera Y; Saito H
Int J Hematol; 1999 Feb; 69(2):112-8. PubMed ID: 10071461
[TBL] [Abstract][Full Text] [Related]
14. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for separating graft-versus-leukemia effect from graft-versus-host disease.
Jiang YZ; Mavroudis DA; Dermime S; Molldrem J; Hensel NF; Barrett AJ
Bone Marrow Transplant; 1997 May; 19(9):899-903. PubMed ID: 9156263
[TBL] [Abstract][Full Text] [Related]
15. Anti-host cytotoxic T cells of bone marrow transplant recipients with or without graft-versus-host disease are equally sensitive to cyclosporin A.
Liem LM; van Noort JT; Goulmy E
Bone Marrow Transplant; 1996 Jul; 18(1):73-8. PubMed ID: 8831998
[TBL] [Abstract][Full Text] [Related]
16. Frequency of bone marrow T cells responding to HLA-identical non-leukemic and leukemic stimulator cells.
Hoffmann T; Theobald M; Bunjes D; Weiss M; Heimpel H; Heit W
Bone Marrow Transplant; 1993 Jul; 12(1):1-8. PubMed ID: 8374531
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
19. The putative role of HLA-C recognition in graft versus host disease (GVHD) and graft rejection after unrelated bone marrow transplantation (BMT).
Bishara A; Amar A; Brautbar C; Condiotti R; Lazarovitz V; Nagler A
Exp Hematol; 1995 Dec; 23(14):1667-75. PubMed ID: 8542963
[TBL] [Abstract][Full Text] [Related]
20. TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells.
Dolstra H; Fredrix H; van der Meer A; de Witte T; Figdor C; van de Wiel-van Kemenade E
Bone Marrow Transplant; 2001 May; 27(10):1087-93. PubMed ID: 11438826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
